Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 05/19/2026 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock CALT vs. DNTH, INDV, LEGN, NAMS, and KNSAShould you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? MarketBeat compares Calliditas Therapeutics AB (publ) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calliditas Therapeutics AB (publ) include Dianthus Therapeutics (DNTH), Indivior (INDV), Legend Biotech (LEGN), NewAmsterdam Pharma (NAMS), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. CALT vs. DNTHCALT vs. INDVCALT vs. LEGNCALT vs. NAMSCALT vs. KNSAHow does Calliditas Therapeutics AB (publ) compare to Dianthus Therapeutics?Dianthus Therapeutics (NASDAQ:DNTH) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Is DNTH or CALT more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-12,998.50% -27.30% -25.91% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Do institutionals and insiders believe in DNTH or CALT? 47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, DNTH or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$2.04M2,414.35-$162.34M-$4.13N/ACalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A Which has more risk & volatility, DNTH or CALT? Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Does the media prefer DNTH or CALT? In the previous week, Dianthus Therapeutics had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Dianthus Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Dianthus Therapeutics' average media sentiment score of 0.25 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dianthus Therapeutics Neutral Calliditas Therapeutics AB (publ) Neutral Do analysts rate DNTH or CALT? Dianthus Therapeutics presently has a consensus price target of $117.82, indicating a potential upside of 30.78%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryDianthus Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 17 factors compared between the two stocks.How does Calliditas Therapeutics AB (publ) compare to Indivior?Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings. Is CALT or INDV more profitable? Indivior has a net margin of 19.44% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Indivior 19.44%-219.26%29.40% Which has better earnings and valuation, CALT or INDV? Indivior has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/AIndivior$1.24B3.69$210M$1.9519.22 Does the media refer more to CALT or INDV? In the previous week, Indivior had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 0.33 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Indivior Neutral Which has more volatility and risk, CALT or INDV? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Indivior has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Do analysts rate CALT or INDV? Indivior has a consensus price target of $39.33, indicating a potential upside of 4.94%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indivior 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in CALT or INDV? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryIndivior beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.How does Calliditas Therapeutics AB (publ) compare to Legend Biotech?Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Is CALT or LEGN more profitable? Legend Biotech has a net margin of -21.98% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Legend Biotech's return on equity of -24.92% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Legend Biotech -21.98%-24.92%-14.87% Do institutionals & insiders hold more shares of CALT or LEGN? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, CALT or LEGN? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/ALegend Biotech$1.14B4.60-$296.80M-$0.68N/A Does the media favor CALT or LEGN? In the previous week, Legend Biotech had 7 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 7 mentions for Legend Biotech and 0 mentions for Calliditas Therapeutics AB (publ). Legend Biotech's average media sentiment score of 0.07 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Legend Biotech Neutral Do analysts recommend CALT or LEGN? Legend Biotech has a consensus target price of $59.00, suggesting a potential upside of 108.08%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Legend Biotech 1 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility & risk, CALT or LEGN? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. SummaryLegend Biotech beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.How does Calliditas Therapeutics AB (publ) compare to NewAmsterdam Pharma?Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends. Which has preferable valuation and earnings, CALT or NAMS? Calliditas Therapeutics AB (publ) has higher revenue and earnings than NewAmsterdam Pharma. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/ANewAmsterdam Pharma$22.50M186.65-$203.82M-$1.79N/A Is CALT or NAMS more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% NewAmsterdam Pharma -943.23%-26.49%-24.37% Which has more risk & volatility, CALT or NAMS? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Do analysts prefer CALT or NAMS? NewAmsterdam Pharma has a consensus price target of $48.00, suggesting a potential upside of 33.61%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do insiders and institutionals believe in CALT or NAMS? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor CALT or NAMS? In the previous week, NewAmsterdam Pharma had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for NewAmsterdam Pharma and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral NewAmsterdam Pharma Neutral SummaryNewAmsterdam Pharma beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.How does Calliditas Therapeutics AB (publ) compare to Kiniksa Pharmaceuticals International?Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Do analysts rate KNSA or CALT? Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, indicating a potential upside of 11.11%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, research analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is KNSA or CALT more profitable? Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International9.69% 13.26% 9.86% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Which has more risk and volatility, KNSA or CALT? Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Does the media refer more to KNSA or CALT? In the previous week, Kiniksa Pharmaceuticals International had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 0 mentions for Calliditas Therapeutics AB (publ). Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Overall Sentiment Kiniksa Pharmaceuticals International Positive Calliditas Therapeutics AB (publ) Neutral Do insiders and institutionals believe in KNSA or CALT? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, KNSA or CALT? Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$677.56M6.22$59.01M$0.9060.86Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A SummaryKiniksa Pharmaceuticals International beats Calliditas Therapeutics AB (publ) on 14 of the 16 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition ExportMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$918.91M$6.33B$12.33BDividend YieldN/A4.84%2.80%5.36%P/E Ratio-21.621.4220.8825.51Price / Sales0.74116.26520.5073.06Price / CashN/A20.0743.1855.00Price / Book37.747.5410.017.03Net Income-$43.96M-$3.91M$3.54B$334.92M7 Day PerformanceN/A-2.54%0.38%-0.40%1 Month PerformanceN/A74.17%-0.02%1.07%1 Year PerformanceN/A122.79%35.07%34.65% Calliditas Therapeutics AB (publ) Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60BN/A180DNTHDianthus Therapeutics2.5525 of 5 stars$86.15-1.1%$117.82+36.8%+364.3%$4.76B$2.04MN/A80INDVIndivior3.4603 of 5 stars$38.28-1.4%$39.33+2.8%+228.6%$4.74B$1.29B19.631,051LEGNLegend Biotech4.0229 of 5 stars$28.26+10.5%$58.31+106.3%-6.5%$4.73B$1.03BN/A2,965Analyst ForecastGap DownNAMSNewAmsterdam Pharma2.0895 of 5 stars$38.89-1.8%$48.00+23.4%+84.8%$4.55B$22.57MN/A4Gap Down Related Companies and Tools Related Companies Dianthus Therapeutics Alternatives Indivior Alternatives Legend Biotech Alternatives NewAmsterdam Pharma Alternatives Kiniksa Pharmaceuticals International Alternatives Travere Therapeutics Alternatives Amneal Pharmaceuticals Alternatives MANE Alternatives Crinetics Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
